微小RNA-134-5p通过整合素β1/基质金属蛋白酶2/磷脂酰肌醇-3-激酶/蛋白激酶B信号通路抑制骨肉瘤的恶性表型。

MiR-134-5p inhibits the malignant phenotypes of osteosarcoma via ITGB1/MMP2/PI3K/Akt pathway.

作者信息

Yan Lei, Zhou Ruhao, Feng Yi, Li Ruoqi, Zhang Long, Pan Yongchun, Qiao Xiaochen, Li Pengcui, Wei Xiaochun, Xu Chaojian, Li Yuan, Niu Xiaochen, Sun Xiaojuan, Lv Zhi, Tian Zhi

机构信息

Second Clinical Medical College, Shanxi Medical University, 382 Wuyi Road, Taiyuan, Shanxi, 030001, China.

Department of orthopedics, The Second Hospital of Shanxi Medical University, Shanxi Key laboratory of Bone and Soft Tissue injury repair, 382 Wuyi Road, Taiyuan, Shanxi, 030001, China.

出版信息

Cell Death Discov. 2024 Apr 25;10(1):193. doi: 10.1038/s41420-024-01946-z.

Micro RNAs (miRs) have been implicated in various tumorigenic processes. Osteosarcoma (OS) is a primary bone malignancy seen in adolescents. However, the mechanism of miRs in OS has not been fully demonstrated yet. Here, miR-134-5p was found to inhibit OS progression and was also expressed at significantly lower levels in OS tissues and cells relative to normal controls. miR-134-5p was found to reduce vasculogenic mimicry, proliferation, invasion, and migration of OS cells, with miR-134-5p knockdown having the opposite effects. Mechanistically, miR-134-5p inhibited expression of the ITGB1/MMP2/PI3K/Akt axis, thus reducing the malignant features of OS cells. In summary, miR-134-5p reduced OS tumorigenesis by modulation of the ITGB1/MMP2/PI3K/Akt axis, suggesting the potential for using miR-134-5p as a target for treating OS.

微小RNA（miR）已被证明参与多种肿瘤发生过程。骨肉瘤（OS）是青少年中常见的原发性骨恶性肿瘤。然而，miR在骨肉瘤中的作用机制尚未完全阐明。在本研究中，我们发现miR-134-5p能够抑制骨肉瘤进展，并且在骨肉瘤组织和细胞中的表达水平相对于正常对照显著降低。研究发现，miR-134-5p能够减少骨肉瘤细胞的血管生成拟态、增殖、侵袭和迁移，而敲低miR-134-5p则会产生相反的效果。机制上，miR-134-5p抑制ITGB1/MMP2/PI3K/Akt信号轴的表达，从而降低骨肉瘤细胞的恶性特征。综上所述，miR-134-5p通过调节ITGB1/MMP2/PI3K/Akt信号轴减少骨肉瘤的肿瘤发生，提示miR-134-5p有可能作为治疗骨肉瘤的靶点。